Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04298242 · ClinicalTrials.gov registry record · NA
Magnetic Resonance Guided High Intensity Focused Ultrasound in Advanced Pancreatic Adenocarcinoma Treatment
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT04298242: Completed NA study, sponsored by Stanford University.
NCT04298242 is a NA study that has completed, run by Stanford University. The registered enrollment target is 1 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04298242, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
The primary purpose of this protocol is to assess the ExAblate 2100 MR guided high intensity focused ultrasound device as an intervention for treatment of advanced stage pancreatic adenocarcinoma.
Interventions
- DEVICE ExAblate 2100
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2020-11-22 |
| Est. Completion | 2021-06-15 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04298242
The ClinicalTrials.gov registry entry for NCT04298242 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ExAblate 2100 is the first listed.
NCT04298242 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04298242 about?
NCT04298242 is a clinical study titled "Magnetic Resonance Guided High Intensity Focused Ultrasound in Advanced Pancreatic Adenocarcinoma Treatment". The primary purpose of this protocol is to assess the ExAblate 2100 MR guided high intensity focused ultrasound device as an intervention for treatment of advanced stage pancreatic adenocarcinoma.
What is the current status of trial NCT04298242?
This trial is currently completed. It is a NA study. The enrollment target is 1 participants. The study started on 2020-11-22. Estimated completion is 2021-06-15.
What interventions are being tested in trial NCT04298242?
The interventions under investigation include: ExAblate 2100 (DEVICE).
Who is sponsoring clinical trial NCT04298242?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.